FY2025 EPS Estimates for CorMedix Raised by HC Wainwright

CorMedix Inc (NASDAQ:CRMD) – Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for CorMedix in a research note issued on Thursday, September 25th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $1.96 per share for the year, up from their previous forecast of $1.41. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s Q4 2025 earnings at $0.90 EPS, FY2026 earnings at $2.36 EPS and FY2028 earnings at $2.19 EPS.

CRMD has been the topic of several other research reports. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of CorMedix in a research report on Tuesday, September 9th. D Boral Capital lowered CorMedix from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 30th. Needham & Company LLC lifted their price target on CorMedix from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, June 24th. Wall Street Zen raised CorMedix from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 13th. Finally, D. Boral Capital lowered CorMedix from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

CorMedix Stock Down 1.9%

CRMD stock opened at $11.63 on Monday. The business has a 50 day moving average price of $12.38 and a 200 day moving average price of $11.32. The stock has a market cap of $907.84 million, a price-to-earnings ratio of 15.51 and a beta of 1.76. CorMedix has a fifty-two week low of $5.60 and a fifty-two week high of $17.43.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.08. The firm had revenue of $39.74 million during the quarter, compared to analysts’ expectations of $29.88 million. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The firm’s revenue was up 4830.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.25) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board acquired a new position in shares of CorMedix in the second quarter valued at approximately $42,000. USA Financial Formulas acquired a new position in shares of CorMedix in the second quarter valued at approximately $55,000. Russell Investments Group Ltd. boosted its stake in shares of CorMedix by 22.2% in the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock valued at $81,000 after buying an additional 1,190 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of CorMedix by 17.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $81,000 after buying an additional 998 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in shares of CorMedix in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Alan W. Dunton sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $13.13, for a total value of $131,300.00. Following the transaction, the director owned 40,250 shares of the company’s stock, valued at approximately $528,482.50. The trade was a 19.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joseph Todisco sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $13.00, for a total value of $650,000.00. Following the completion of the transaction, the chief executive officer directly owned 509,496 shares in the company, valued at approximately $6,623,448. The trade was a 8.94% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 163,997 shares of company stock worth $2,163,617. 5.30% of the stock is currently owned by company insiders.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.